A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
Public ClinicalTrials.gov record NCT03060538. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease
Study identification
- NCT ID
- NCT03060538
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 154 participants
Conditions and interventions
Interventions
- BFKB8488A Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 4, 2017
- Primary completion
- Dec 12, 2019
- Completion
- Dec 12, 2019
- Last update posted
- Mar 26, 2020
2017 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group Cullman | Anniston | Alabama | 36207 | — |
| Pinnacle Research Group; Llc, Central | Anniston | Alabama | 36207 | — |
| Southern California Research Center, Inc. | Coronado | California | 92118 | — |
| Stanford Health Care | Stanford | California | 94305 | — |
| Diabetes Research Center | Tustin | California | 92780 | — |
| MD Clinical | Hallandale | Florida | 33009 | — |
| Premier Research Associate, Inc | Miami | Florida | 33165 | — |
| Agile Clinical Research Trials | Atlanta | Georgia | 30328 | — |
| MidWest Clinical Research | Overland Park | Kansas | 66209 | — |
| Hassman Research Institute | Berlin | New Jersey | 08009 | — |
| Carolina Research Center at Jones Family Practice | Shelby | North Carolina | 28150 | — |
| New Orleans Center for Clinical Research | Knoxville | Tennessee | 37920 | — |
| Texas Clinical Research Institute, LLC | Arlington | Texas | 76012 | — |
| Dallas Diabetes & Endocrine Center | Dallas | Texas | 75230 | — |
| Clinical Trials of Texas Incorporated | San Antonio | Texas | 78229 | — |
| Northeast Clinical Research of San Antonio LLC | San Antonio | Texas | 78249 | — |
| Consano Clinical Research | Shavano Park | Texas | 78231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03060538, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2020 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03060538 live on ClinicalTrials.gov.